புஜிஃபில்ம் டோயாமா இரசாயன News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புஜிஃபில்ம் டோயாமா இரசாயன. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புஜிஃபில்ம் டோயாமா இரசாயன Today - Breaking & Trending Today

Appili concludes enrolment in sub-study of Covid-19 antiviral treatment

Appili concludes enrolment in sub-study of Covid-19 antiviral treatment
clinicaltrialsarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicaltrialsarena.com Daily Mail and Mail on Sunday newspapers.

Yoav Golan , Avigan Reeqonu , Avigan Reeqonus , Appili Therapeutics , Fujifilm Toyama Chemical , புஜிஃபில்ம் டோயாமா இரசாயன ,

Global Response Aid Reports Midyear Sales Results for COVID Drug

/PRNewswire/ Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its anti-viral tablet. ....

United Arab Emirates , United States , Mitch Wilson , Fujifilm Toyama , Mary Obrien , Holdings Corporation , Services Active Ingredients , Reddy Laboratories Ltd , Global Response Aid , Fujifilm Toyama Chemical , Active Ingredients , Global Generics , Proprietary Products , ஒன்றுபட்டது அரபு அமீரகங்கள் , ஒன்றுபட்டது மாநிலங்களில் , மிட்ச் வில்சன் , புஜிஃபில்ம் டோயாமா , மேரி ஓபிறீேன் , ஹோல்டிங்ஸ் நிறுவனம் , சேவைகள் செயலில் பொருட்கள் , சிவப்பு ஆய்வகங்கள் லிமிடெட் , உலகளாவிய பதில் உதவி , புஜிஃபில்ம் டோயாமா இரசாயன , செயலில் பொருட்கள் , உலகளாவிய ஜெநெரிக்ஸ் , ப்ரொப்ரைடரீ ப்ராடக்ட்ஸ் ,

Anti-Viral backed by GRA on track to deliver Covid-19 home treatment

Anti-Viral backed by GRA on track to deliver Covid-19 home treatment
DUBAI, 1 hours, 53 minutes
ago
Healthcare solutions provider Global Response Aid (GRA) announced that a Phase 3 US-Canada clinical trial of anti-viral Avigan (Reeqonus) will continue amid signs the drug could be effective in the treatment of patients with mild to moderate cases of Covid-19.

An independent Data and Safety Monitoring Board (DSMB) recognised by the US Food and Drug Administration has recommended continuation without modification of an ongoing Phase 3 PRESECO (PREventing SEvere COvid-19) trial that is evaluating Avigan as a potential outpatient oral therapy for patients with mild-to-moderate Covid-19.

Interim results indicate that Avigan, the brand name for generic Favipiravir, could shorten recovery times and prevent progression in Covid-19 patients in the early stage of infection. The conclusion of the midterm analysis is that, if current trends continue, t ....

United Arab Emirates , Mitch Wilson , Richard Kaszynski , Avigan Reeqonus , Drug Administration , Tradearabia News Service , Global Response Aid , Safety Monitoring Board , Appili Therapeutics , Fujifilm Toyama Chemical , Arabia News , Rade Arabia , Iddle East Trade News , Cc Business News , Ndustry News , Trade News , Usiness Directory , Roject News , Remium Content , ஒன்றுபட்டது அரபு அமீரகங்கள் , மிட்ச் வில்சன் , உலகளாவிய பதில் உதவி , பாதுகாப்பு கண்காணிப்பு பலகை , புஜிஃபில்ம் டோயாமா இரசாயன , அரேபியா செய்தி , வர்த்தகம் செய்தி ,

DIP rejects bid to patent Covid treatment

DIP rejects bid to patent Covid treatment
2
published :
6 May 2021 at 04:44
Vuttikrai: Free for all to produce
The Department of Intellectual Property (DIP) has rejected a request to patent the anti-viral drug Favipiravir which is being administered to patients with few if any Covid-19 symptoms.
Vuttikrai Leewiraphan, the department director-general, ruled that the request by a manufacturer to patent the drug in its tablet form did not constitute an advanced invention under the 1979 Patent Act.
The applicant was allowed to submit additional paperwork but still fell short of qualifying for the patent, he said.
Mr Vuttikrai said nobody could claim exclusive rights to produce or sell Favipiravir in Thailand and both the Government Pharmaceutical Organisation and any private company in Thailand were free to produce it. ....

Krung Thep Mahanakhon , Vuttikrai Leewiraphan , Pol Gen Aswin , Public Health Ministry , Government Pharmaceutical Organisation , Department Of Intellectual Property , Intellectual Property , Fujifilm Toyama Chemical , போல் கேன் அஸ்வின் , பொது ஆரோக்கியம் அமைச்சகம் , அரசு மருந்து ஆர்கநைஸேஶந் , துறை ஆஃப் அறிவுசார் ப்ராபர்டீ , அறிவுசார் ப்ராபர்டீ , புஜிஃபில்ம் டோயாமா இரசாயன ,

Green light for local favipiravir production

Green light for local favipiravir production
4
published :
5 May 2021 at 17:18
Vuttikrai Leewiraphan, director-general of the Department of Intellectual Property.
The Department of Intellectual Property has rejected the developer of the drug favipiravir s latest patent application, paving the way for local production of the antiviral medication now widely used to treat Covid-19 patients.
DIP director-general Vuttikrai Leewiraphan said on Wednesday that the department rejected the patent application after finding it presented no new innovation.
Therefore, no one monopolised favipiravir in Thailand and the Government Pharmaceutical Organization (GPO) and other producers of Thai generic drugs could produce the drug for local use, he said. ....

Vuttikrai Leewiraphan , Government Pharmaceutical Organization , Department Of Intellectual Property , Intellectual Property , Fujifilm Toyama Chemical , அரசு மருந்து ஆர்கநைஸேஶந் , துறை ஆஃப் அறிவுசார் ப்ராபர்டீ , அறிவுசார் ப்ராபர்டீ , புஜிஃபில்ம் டோயாமா இரசாயன ,